Refine
Year of publication
Document Type
- Article (16)
- Doctoral Thesis (1)
Has Fulltext
- yes (17)
Is part of the Bibliography
- no (17)
Keywords
- Cirrhosis (2)
- HBV (2)
- HIV (2)
- Hepatitis C virus (2)
- Protease inhibitor therapy (2)
- hepatitis C virus (2)
- APRI (1)
- Antiviral agents (1)
- Antiviral immune response (1)
- Antiviral therapy (1)
- Biomarkers (1)
- Chronic hepatitis (1)
- DAA (1)
- Extracellular matrix proteins (1)
- FIB-4 (1)
- HCV (1)
- Hepatitis C, Chronic (1)
- Hepatocellular carcinoma (1)
- Interferons (1)
- Liver cirrhosis (1)
- Liver transplantation (1)
- Medical education (1)
- NS5A (1)
- RAS (1)
- Specimen preparation and treatment (1)
- Viral load (1)
- acoustic radiation force impulse imaging (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- arachidonic acid (1)
- biomarker (1)
- co-infection (1)
- core expression (1)
- direct-acting antivirals (1)
- exosomes (1)
- fibrotest (1)
- genotype G (1)
- hepatic fibrosis (1)
- hepatitis C (1)
- immune escape (1)
- innate immunity (1)
- insulin resistance (1)
- interferon (1)
- non-invasive fibrosis assessment (1)
- omega-3 fatty acids (1)
- point shear wave elastography (1)
- prevalence (1)
- protein evolution (1)
- protein folding (1)
- resistance mutation (1)
- serine protease (NS3-4A) (1)
- sphingolipid (1)
- transient elastography (1)
- viral fitness (1)
- virologic failure (1)
Although direct-acting antiviral medications effectively cure hepatitis C in most patients, sometimes treatment selects for resistant viruses, causing antiviral drugs to be either ineffective or only partially effective. Multidrug resistance is common in patients for whom DAA treatment fails. Older patients and patients with advanced liver diseases are more likely to select drug-resistant viruses. Collective efforts from international communities and governments are needed to develop an optimal approach to managing drug resistance and preventing the transmission of resistant viruses.